Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02504489
Title Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC (DUBLIN-3)
Acronym DUBLIN-3
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors BeyondSpring Pharmaceuticals Inc.
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | AUS

Additional content available in CKB BOOST